Interim Results Presented at EASL from PROVE 1 Clinical Trial of
Investigational Drug Telaprevir in Patients with Genotype 1
Hepatitis C
BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breakerpresentation at the 42nd Annual Meeting of the European Associationfor the Study of the Liver (EASL), researchers today presented datafrom a planned interim analysis of the PROVE 1 clinical trial,which is the first trial to evaluate short-duration therapy withthe investigational hepatitis C protease inhibitor
telaprevir (TVR,...
Vertex Pharmaceuticals Announces New Data for Investigational HCV
Protease Inhibitor Telaprevir to be Presented at 42nd Annual
Meeting of the European Association for the Study of the Liver
(EASL)
BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New datasupporting the clinical development of
telaprevir (VX-950), one ofthe most advanced investigational oral protease inhibitors for thetreatment of hepatitis C virus (HCV) infection, will be presentedat the 42nd Annual Meeting of the European Association for theStudy of the Liver (EASL) in Barcelona this week. In total, nineabstracts re...